Form 4: Boston Scientific Executive Sells Shares After Performance Share Units Vest
SEC Form 4 Filing
Jeffrey B. Mirviss, EVP & President of Peripheral Interventions at Boston Scientific, reports the vesting of performance share units and subsequent sale of shares.
Summary
- Jeffrey B. Mirviss, an executive at Boston Scientific, reported transactions involving the company's common stock.
- On January 1, 2025, 10,430 performance share units vested and were converted into common stock.
- Also on January 1, 2025, 3,278 shares were disposed of to cover tax obligations at a price of $89.32 per share.
- On January 3, 2025, Mirviss sold 7,152 shares at a weighted average price of $89.8571 per share, with prices ranging from $89.523 to $90.15.
- Following these transactions, Mirviss directly owns 28,454 shares of Boston Scientific common stock.
Sentiment
Score: 5
Explanation: The document is a routine Form 4 filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, as it primarily reflects pre-planned actions under a 10b5-1 trading plan and vesting of previously awarded compensation.
Industry Context
Executive stock transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects; however, transactions under 10b5-1 plans are pre-scheduled and may not reflect current sentiment.
Comparison to Industry Standards
- Executive compensation packages often include performance-based equity awards like the performance share units described in the filing.
- Vesting schedules and performance metrics vary across companies, but free cash flow and service period requirements are common.
- Rule 10b5-1 trading plans are a standard practice for executives to manage their stock sales while avoiding insider trading concerns.
- Comparable companies like Medtronic and Abbott also utilize similar equity compensation strategies for their executives.
Stakeholder Impact
- The stock sale may have a minor, temporary impact on the stock price.
- The vesting of performance share units reflects the company's performance against its financial plan.
Key Dates
| Date | Description |
|---|---|
| February 10, 2022 | Reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program |
| December 31, 2022 | End of the one-year performance period for the performance share units. |
| February 14, 2023 | The number of the target performance share units as to which the performance criteria had been satisfied was determined. |
| February 28, 2024 | Adoption date of the Rule 10b5-1 trading plan. |
| June 30, 2024 | Shares acquired under the Company's Employee Stock Purchase Plan. |
| December 31, 2024 | Completion of the three-year individual service period for the performance share units. |
| January 1, 2025 | Vesting of 10,430 performance share units and disposal of 3,278 shares for tax obligations. |
| January 3, 2025 | Sale of 7,152 shares under Rule 10b5-1 trading plan. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.